The virologic effect of high dose recombinant soluble cd4 rscd4 in hiv positive individuals
Schacker, T.; Coombs, R.; Collier, A.; Fox, I.; Eggert, E.; Nelson, K.; Corey, L.
Antiviral Research 17(Suppl 1): 133
1992
ISSN/ISBN: 0166-3542 Accession: 033975858
Full Text Article emailed within 1 workday: $29.90
Related References
Paredes, R.; Puig, T.; Arnó, A.; Negredo, E.; Balagué, M.; Bonjoch, A.; Jou, A.; Tuldrà, A.; Tural, C.; Sirera, G.; Veny, A.; Romeu, J.; Ruiz, L.; Clotet, B. 1999: High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response Journal of Acquired Immune Deficiency Syndromes 22(2): 132-138Pimstone, N.R.; Canio, J.B.; Powell, J.S.; Kokosinski, J.; Saicheur, T. 2000: Virologic response in re-treatment of chronic hepatitis C interferon virologic non-responders and responder-relapsers IFN induction followed by combination ribavirin High dose IFN Gastroenterology 118(4 Suppl 2 Pt 2): AASLD A148
Sachs, M.; Fong, K.L.; Blanchard, L.; Wikler, M. 1993: High-dose recombinant soluble CD4 in patients with HIV-1 infection Abstracts of the General Meeting of the American Society for Microbiology 93: 437
Schacker, T.; Coombs, R.; Collier, A.; Fox, I.; Alam, J.; Nelson, K.; Eggert, E.; Wolinsky, S.; Corey, L. 1992: High dose intravenous recombinant soluble cd4 rscd4 inactivates hiv 1 in vivo Clinical Research 40(2): 333A
Schacker, T.; Coombs, R.W.; Collier, A.C.; Zeh, J.E.; Fox, I.; Alam, J.; Nelson, K.; Eggert, E.; Corey, L. 1994: The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia Journal of Infectious Diseases 169(1): 37-40
De Melo, M.G.ça.; Varella, I.; Gorbach, P.M.; Sprinz, E.; Santos, B.; de Melo Rocha, T.í; Simon, M.; Almeida, M.; Lira, R.; Chaves, M.C.; Baker, Z.; Kerin, T.; Nielsen-Saines, K. 2019: Antiretroviral adherence and virologic suppression in partnered and unpartnered HIV-positive individuals in southern Brazil Plos one 14(2): E0212744
Larsson, M.; Jin, X.; Ramratnam, B.; Ogg, G.S.; Engelmayer, J.; Demoitie, M.A.; McMichael, A.J.; Cox, W.I.; Steinman, R.M.; Nixon, D.; Bhardwaj, N. 1999: A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals Aids 13(7): 767-777
Pimstone, N.R.; Canio, J.B.; Powell, J.S.; Chaing, M.; Kokosinski, J.; Saicheur, T. 2000: Virologic response in re-treatment of chronic hepatitis C interferon virologic non-responders and responder-relapsers INF induction followed by combination Ribavirin vs combination Ribavirin High dose IFN Hepatology 32(4 Pt 2): 557A
Elbeik, T.; Guthrie, J.; Horton, C.; Drews, B.; Staprans, S.; Grant, R.; Buchbinder, S.; Feinberg, M. 1996: Virologic assessment of healthy long term positive individuals from the San Francisco City Clinic cohort INFECTIOUS DISEASES SOCIETY OF AMERICA Author, NATIONAL INSTITUTES OF HEALTH Author, CENTERS FOR DISEASE CONTROL and PREVENTION Author 3rd Conference on retroviruses and opportunistic infections : 100
Ghebremichael, M S.; Hansen, N B.; Zhang, H; Sikkema, K J. 2006: The dose effect of a group intervention for bereaved HIV-positive individuals Group Dynamics 10(3): 167-180
Yoo, Y.K.; Gavaler, J.B.; Chen, K.; Whiteside, T.L.; van Thiel, D.H. 1990: The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals Clinical and Experimental Immunology 82(2): 338-343
Zeller, W.; Fiedler, W.; Schaefer, B.; Hossfeld, D.K. 1994: Shedding of soluble ICAM-1 and TNF-receptor molecules in response to treatment with high and low dose recombinant IL-2 in patients with solid tumors Journal of Cancer Research and Clinical Oncology 120(Suppl ): R123
Grennan, J.Troy.; Loutfy, M.R.; Su, D.; Harrigan, P.Richard.; Cooper, C.; Klein, M.; Machouf, N.; Montaner, J.S.G.; Rourke, S.; Tsoukas, C.; Hogg, B.; Raboud, J.; Hosein, S.; Lemay, B.; Margolese, S.; Ssengendo, E.; Aykroyd, G.; Balfour, L.; Bayoumi, A.; Cairney, J.; Calzavara, L.; Cooper, C.; Gough, K.; Guillemi, S.; Harrigan, P..Richard.; Harris, M.; Hatzakis, G.; Hogg, R.; Kilby, D.; Klein, M.; Lalonde, R.; Lima, V.; Loutfy, M.; Machouf, N.; Mills, E.; Millson, P.; Montaner, J.; Moore, D.; Palmer, A.; Raboud, J.; Rachlis, A.; Read, S.; Rourke, S.; Smieja, M.; Sali 2012: Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis Journal of Infectious Diseases 205(8): 1230-1238
Cain, L.E.; Caniglia, E.C.; Phillips, A.; Olson, A.; Muga, R.; Pérez-Hoyos, S.; Abgrall, S.; Costagliola, D.; Rubio, R.; Jarrín, I.; Bucher, H.; Fehr, J.; van Sighem, A.; Reiss, P.; Dabis, F.ço.; Vandenhende, M.-A.; Logan, R.; Robins, J.; Sterne, J.A.C.; Justice, A.; Tate, J.; Touloumi, G.; Paparizos, V.; Esteve, A.; Casabona, J.; Seng, R.ém.; Meyer, L.; Jose, S.; Sabin, C.; Hernán, M.A. 2016: Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-positive individuals Medicine 95(41): E5133
Geraix, J. 2008: Effect of soluble fiber on hypertriglyceridemia and immune profile in HIV-positive individuals undergoing highly active antiretroviral therapy Journal of Venomous Animals and Toxins Including Tropical Diseases 14(2): 386-387